Antigenics has withdrawn its EU filing following EMEA’s negative opinion on its marketing authorization application for kidney cancer vaccine Oncophage.
With no approved therapy currently available to treat Neimann-Pick Disease, FDA granted Actelion's sBLA for Zavesca (miglustat) priority review and advisory committee will evaluate the neurologic Jan. 12.
Financings of the Fortnight: Belgian-based J&J spin-out Movetis filed to raise up to more than €112 million in what could be Europe's first biopharma IPO since Italian biotech Molmed raised €56 million in February 2008.
